US FDA approves Amgen-AstraZeneca’s Tezspire for asthma treatment
Pharmaceutical Technology
FEBRUARY 3, 2023
It was initially FDA-approved in December 2021 and is claimed to be the only biologic approved to treat severe asthma with no phenotype or biomarker limitation. In the PATH-HOME trial, 92% of healthcare providers, patients and caregivers successfully administered Tezspire in the clinic and at home throughout the study.
Let's personalize your content